Evidence map›Paper›PMID 34146376›Full record

ReviewThe FEBS journal2022

Contributions of PD-L1 reverse signaling to dendritic cell trafficking.

Beth Ann Jirón Tamburini

Open access · greenAbstract readReview
In one paragraph

Review in The FEBS journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Establishment of an in vitro evaluation method for immunomodulatory functions of yeast strains.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Beth Ann Jirón TamburiniDivision of Gastroenterology and Hepatology, Department of Medicine, University of Colorado School of Medicine Aurora, CO, USA.ORCID 0000-0003-1991-231X
University of Colorado Denver · US

Funding

Cooperation between lymphatic stroma and hematopoietic cells shapes protective immunityR01AI121209 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Beth Ann Tamburini · 2016 to 2026
$4.5M
PD-L1 reverse signaling in dermal DCs promotes DC migration and skin immunity to cutaneous pathogensR01AI155474 · NIAID · UNIVERSITY OF COLORADO DENVER · PI TAMBURINI, BETH ANN · 2020 to 2024
$2.3M
Molecular tracking of antigen following vaccinationR21AI155929 · NIAID · UNIVERSITY OF COLORADO DENVER · PI TAMBURINI, BETH ANN · 2021 to 2022
$417k
NIAID NIH HHS R01 AI121209NIAID NIH HHS R01 AI155474NIAID NIH HHS R21 AI155929
6 · The paper itself

Abstract

Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) interactions are critical for dampening the immune response to both self and foreign antigens. The signaling of PD-L1 via its cytoplasmic domain, rather than through its interactions with PD-1 via the extracellular domain, has been termed PD-L1 reverse signaling. While this signaling is beneficial for cancer progression, little is understood about the consequences of PD-L1 reverse signaling in immune cells that express PD-L1 at steady state or in response to infection. Loss of PD-L1 during infection leads to unchecked T-cell proliferation and increased autoimmune T-cell responses. While the T-cell intrinsic role of PD-1 for inhibiting T-cell responses has been well explored, little to no effort has been directed at investigating the consequences of PD-L1 reverse signaling on the DCs interacting with PD-1+ T cells. We recently reported a defect in dendritic cell (DC) trafficking from the skin to the draining lymph node (LN) following immunization or infection in the absence of PD-L1. We demonstrated that a region within the cytoplasmic tail was responsible for the defect in DC trafficking. Here, we review the processes involved in DC trafficking and highlight what we know about PD-L1 expression, PD-L1 post-translational modifications, PD-L1 intracellular interactions, and PD-L1 extracellular interactions.

Indexed as

B7-H1 AntigenProgrammed Cell Death 1 ReceptorDendritic CellsLymphocyte ActivationB7-H1 AntigenCD274 protein, humanProgrammed Cell Death 1 ReceptorCD80 signalingdendritic cell migrationdendritic cell traffickinginterferonPD-L1 reverse signaling

Identifiers

PMID34146376
PMCPMC8684559
OpenAlexW3169146894

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.